IQGAP1 Copy Gain Detection in Thyroid Cancer Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for diagnosing, prognosing, and treating human cancers, particularly in stratifying and treating cancers based on genetic characteristics such as IQGAP1 copy number gain, which is associated with increased invasiveness and aggressiveness in thyroid cancer.
Innovation Solution
Detecting increased copy numbers of IQGAP1 in tissue samples to categorize and treat cancers, using inhibitors to target IQGAP1 protein or its expression, and identifying candidate drugs that inhibit IQGAP1's binding to E-cadherin to diminish cancer invasiveness and spread.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If IQGAP1 copy number detection is used to categorize cancer tissue samples, then cancer prognosis accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent replaces complex diagnostic procedures with a molecular biology-based detection method using PCR or FISH to measure IQGAP1 copy number. This substitution of mechanical/diagnostic systems with molecular detection techniques improves prognosis accuracy while standardizing the diagnostic process.
2Object-affected harmful factors
If IQGAP1 inhibitors are administered to treat cancer, then cancer invasiveness is reduced, but treatment specificity requirements increase
Solution Approach 1:
The patent applies local quality by targeting IQGAP1 specifically in cancer cells that overexpress this protein. The inhibitor is designed to bind to IQGAP1's specific structure (including its GAP domain and IQ motifs), providing localized action against cancer cells with IQGAP1 amplification while sparing normal cells, thus reducing invasiveness with appropriate specificity.
3Productivity
If candidate drugs are screened for IQGAP1-E-cadherin binding inhibition, then drug discovery efficiency is improved, but screening complexity increases
Solution Approach 1:
The patent extracts the specific binding interaction between IQGAP1 and E-cadherin as the target for drug screening. By focusing on this single protein-protein interaction interface, the screening process can use simplified assays that measure inhibition of this specific binding event, improving drug discovery efficiency while managing screening complexity through targeted approach.
Data Source
AI summary
We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain≧3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN≧4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knockdown of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers.